nodes	percent_of_prediction	percent_of_DWPC	metapath
Apraclonidine—ADRA1A—Endothelin Pathways—GNAS—adrenal gland cancer	0.0247	0.0249	CbGpPWpGaD
Apraclonidine—ADRA1A—Calcium Regulation in the Cardiac Cell—KCNJ5—adrenal gland cancer	0.0238	0.024	CbGpPWpGaD
Apraclonidine—ADRA2B—G alpha (z) signalling events—GNAS—adrenal gland cancer	0.0236	0.0238	CbGpPWpGaD
Apraclonidine—ADRA2C—G alpha (z) signalling events—GNAS—adrenal gland cancer	0.022	0.0223	CbGpPWpGaD
Apraclonidine—ADRA1A—G alpha (q) signalling events—GNRHR—adrenal gland cancer	0.0198	0.02	CbGpPWpGaD
Apraclonidine—ADRA2A—G alpha (z) signalling events—GNAS—adrenal gland cancer	0.0179	0.0181	CbGpPWpGaD
Apraclonidine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—GNRHR—adrenal gland cancer	0.0177	0.0179	CbGpPWpGaD
Apraclonidine—ADRA2C—Regulation of insulin secretion—PRKACA—adrenal gland cancer	0.0177	0.0179	CbGpPWpGaD
Apraclonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—GNRHR—adrenal gland cancer	0.0161	0.0163	CbGpPWpGaD
Apraclonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—GNRHR—adrenal gland cancer	0.015	0.0152	CbGpPWpGaD
Apraclonidine—ADRA2A—Regulation of insulin secretion—PRKACA—adrenal gland cancer	0.0144	0.0145	CbGpPWpGaD
Apraclonidine—ADRA2C—Regulation of insulin secretion—GNAS—adrenal gland cancer	0.0143	0.0145	CbGpPWpGaD
Apraclonidine—ADRA2C—Integration of energy metabolism—PRKACA—adrenal gland cancer	0.0139	0.014	CbGpPWpGaD
Apraclonidine—ADRA1A—G alpha (12/13) signalling events—CDC42—adrenal gland cancer	0.0134	0.0135	CbGpPWpGaD
Apraclonidine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—GNRHR—adrenal gland cancer	0.0131	0.0133	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR ligand binding—GNRHR—adrenal gland cancer	0.0123	0.0124	CbGpPWpGaD
Apraclonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—GNRHR—adrenal gland cancer	0.0122	0.0123	CbGpPWpGaD
Apraclonidine—ADRA1A—G alpha (q) signalling events—GNRH1—adrenal gland cancer	0.0119	0.012	CbGpPWpGaD
Apraclonidine—ADRA2A—Regulation of insulin secretion—GNAS—adrenal gland cancer	0.0116	0.0118	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR ligand binding—GNRHR—adrenal gland cancer	0.0114	0.0116	CbGpPWpGaD
Apraclonidine—ADRA2A—Integration of energy metabolism—PRKACA—adrenal gland cancer	0.0113	0.0114	CbGpPWpGaD
Apraclonidine—ADRA2C—Integration of energy metabolism—GNAS—adrenal gland cancer	0.0113	0.0114	CbGpPWpGaD
Apraclonidine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—GNRH1—adrenal gland cancer	0.0106	0.0107	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR ligand binding—GNRHR—adrenal gland cancer	0.01	0.0101	CbGpPWpGaD
Apraclonidine—Clonidine—ABCB1—adrenal gland cancer	0.00984	1	CrCbGaD
Apraclonidine—ADRA2B—Platelet activation, signaling and aggregation—SPARC—adrenal gland cancer	0.00965	0.00975	CbGpPWpGaD
Apraclonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—GNRH1—adrenal gland cancer	0.00964	0.00974	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR ligand binding—GNRHR—adrenal gland cancer	0.0093	0.00939	CbGpPWpGaD
Apraclonidine—ADRA2A—Integration of energy metabolism—GNAS—adrenal gland cancer	0.00916	0.00925	CbGpPWpGaD
Apraclonidine—ADRA1A—Calcium Regulation in the Cardiac Cell—PRKACA—adrenal gland cancer	0.00912	0.00921	CbGpPWpGaD
Apraclonidine—ADRA2C—Platelet activation, signaling and aggregation—SPARC—adrenal gland cancer	0.00902	0.00911	CbGpPWpGaD
Apraclonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—GNRH1—adrenal gland cancer	0.00901	0.0091	CbGpPWpGaD
Apraclonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—TSHR—adrenal gland cancer	0.00859	0.00868	CbGpPWpGaD
Apraclonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—TSHR—adrenal gland cancer	0.00803	0.00811	CbGpPWpGaD
Apraclonidine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—GNRH1—adrenal gland cancer	0.00787	0.00795	CbGpPWpGaD
Apraclonidine—ADRA1A—Calcium Regulation in the Cardiac Cell—GNAS—adrenal gland cancer	0.00739	0.00747	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR ligand binding—GNRH1—adrenal gland cancer	0.00734	0.00742	CbGpPWpGaD
Apraclonidine—ADRA2A—Platelet activation, signaling and aggregation—SPARC—adrenal gland cancer	0.00732	0.0074	CbGpPWpGaD
Apraclonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—GNRH1—adrenal gland cancer	0.00732	0.00739	CbGpPWpGaD
Apraclonidine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—TSHR—adrenal gland cancer	0.00702	0.00709	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—GNRHR—adrenal gland cancer	0.00693	0.007	CbGpPWpGaD
Apraclonidine—ADRA2B—Platelet activation, signaling and aggregation—CDC42—adrenal gland cancer	0.00691	0.00698	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR ligand binding—GNRH1—adrenal gland cancer	0.00686	0.00693	CbGpPWpGaD
Apraclonidine—ADRA2B—Platelet activation, signaling and aggregation—IGF2—adrenal gland cancer	0.00666	0.00673	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR ligand binding—TSHR—adrenal gland cancer	0.00654	0.00661	CbGpPWpGaD
Apraclonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—TSHR—adrenal gland cancer	0.00652	0.00659	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—GNRHR—adrenal gland cancer	0.00647	0.00653	CbGpPWpGaD
Apraclonidine—ADRA2C—Platelet activation, signaling and aggregation—CDC42—adrenal gland cancer	0.00646	0.00652	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—GNRHR—adrenal gland cancer	0.00629	0.00635	CbGpPWpGaD
Apraclonidine—ADRA2B—G alpha (i) signalling events—GNAS—adrenal gland cancer	0.00629	0.00635	CbGpPWpGaD
Apraclonidine—ADRA2C—Platelet activation, signaling and aggregation—IGF2—adrenal gland cancer	0.00622	0.00628	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR ligand binding—TSHR—adrenal gland cancer	0.00611	0.00617	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR ligand binding—GNRH1—adrenal gland cancer	0.006	0.00606	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—GNRHR—adrenal gland cancer	0.00588	0.00593	CbGpPWpGaD
Apraclonidine—ADRA2C—G alpha (i) signalling events—GNAS—adrenal gland cancer	0.00587	0.00593	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—GNRHR—adrenal gland cancer	0.00566	0.00571	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR ligand binding—GNRH1—adrenal gland cancer	0.00557	0.00563	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR ligand binding—TSHR—adrenal gland cancer	0.00534	0.0054	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—GNRHR—adrenal gland cancer	0.00526	0.00531	CbGpPWpGaD
Apraclonidine—ADRA2A—Platelet activation, signaling and aggregation—CDC42—adrenal gland cancer	0.00524	0.0053	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—GNRHR—adrenal gland cancer	0.00514	0.00519	CbGpPWpGaD
Apraclonidine—ADRA2A—Platelet activation, signaling and aggregation—IGF2—adrenal gland cancer	0.00505	0.0051	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—SPARC—adrenal gland cancer	0.00498	0.00503	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR ligand binding—TSHR—adrenal gland cancer	0.00497	0.00501	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—GNRHR—adrenal gland cancer	0.00477	0.00482	CbGpPWpGaD
Apraclonidine—ADRA2A—G alpha (i) signalling events—GNAS—adrenal gland cancer	0.00477	0.00482	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—SPARC—adrenal gland cancer	0.00465	0.00469	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—SDHB—adrenal gland cancer	0.00454	0.00458	CbGpPWpGaD
Apraclonidine—ADRA1A—AMPK Signaling—TP53—adrenal gland cancer	0.00437	0.00442	CbGpPWpGaD
Apraclonidine—ADRA2B—G alpha (i) signalling events—POMC—adrenal gland cancer	0.00423	0.00428	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—PRKACA—adrenal gland cancer	0.0042	0.00424	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—GNRH1—adrenal gland cancer	0.00415	0.00419	CbGpPWpGaD
Apraclonidine—ADRA2C—G alpha (i) signalling events—POMC—adrenal gland cancer	0.00395	0.00399	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—PRKACA—adrenal gland cancer	0.00392	0.00396	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—GNRH1—adrenal gland cancer	0.00388	0.00391	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR ligand binding—GNAS—adrenal gland cancer	0.00381	0.00384	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—SPARC—adrenal gland cancer	0.00378	0.00381	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—GNRH1—adrenal gland cancer	0.00377	0.00381	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—GNRHR—adrenal gland cancer	0.00372	0.00375	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—TSHR—adrenal gland cancer	0.0037	0.00374	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—SDHB—adrenal gland cancer	0.00369	0.00372	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—CDC42—adrenal gland cancer	0.00356	0.0036	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR ligand binding—GNAS—adrenal gland cancer	0.00356	0.00359	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—GNRH1—adrenal gland cancer	0.00352	0.00355	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—GNRHR—adrenal gland cancer	0.00347	0.00351	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—TSHR—adrenal gland cancer	0.00345	0.00349	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—SH3KBP1—adrenal gland cancer	0.00345	0.00349	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—IGF2—adrenal gland cancer	0.00343	0.00347	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—GNAS—adrenal gland cancer	0.0034	0.00344	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—GNRH1—adrenal gland cancer	0.00339	0.00342	CbGpPWpGaD
Apraclonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—POMC—adrenal gland cancer	0.00337	0.0034	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—TSHR—adrenal gland cancer	0.00336	0.00339	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—CDC42—adrenal gland cancer	0.00333	0.00336	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—ZNRF3—adrenal gland cancer	0.00325	0.00328	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—SH3KBP1—adrenal gland cancer	0.00323	0.00326	CbGpPWpGaD
Apraclonidine—ADRA2A—G alpha (i) signalling events—POMC—adrenal gland cancer	0.00321	0.00324	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—IGF2—adrenal gland cancer	0.00321	0.00324	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—PRKACA—adrenal gland cancer	0.00319	0.00322	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—GNAS—adrenal gland cancer	0.00318	0.00321	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—GNRH1—adrenal gland cancer	0.00315	0.00318	CbGpPWpGaD
Apraclonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—POMC—adrenal gland cancer	0.00314	0.00318	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—TSHR—adrenal gland cancer	0.00314	0.00317	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR ligand binding—GNAS—adrenal gland cancer	0.00311	0.00314	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—GNRH1—adrenal gland cancer	0.00308	0.00311	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—GNRHR—adrenal gland cancer	0.00303	0.00306	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—ZNRF3—adrenal gland cancer	0.00303	0.00306	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—TSHR—adrenal gland cancer	0.00302	0.00305	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—RRM1—adrenal gland cancer	0.00292	0.00295	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—SDHD—adrenal gland cancer	0.00292	0.00295	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR ligand binding—GNAS—adrenal gland cancer	0.00289	0.00292	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—GNRH1—adrenal gland cancer	0.00286	0.00289	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—SH3KBP1—adrenal gland cancer	0.00282	0.00285	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—GNRHR—adrenal gland cancer	0.00282	0.00285	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—TSHR—adrenal gland cancer	0.00281	0.00283	CbGpPWpGaD
Apraclonidine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—POMC—adrenal gland cancer	0.00275	0.00278	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—TSHR—adrenal gland cancer	0.00274	0.00277	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—CDC42—adrenal gland cancer	0.0027	0.00273	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—ZNRF3—adrenal gland cancer	0.00265	0.00268	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—SH3KBP1—adrenal gland cancer	0.00262	0.00265	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—IGF2—adrenal gland cancer	0.00261	0.00263	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—GNAS—adrenal gland cancer	0.00258	0.00261	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR ligand binding—POMC—adrenal gland cancer	0.00256	0.00259	CbGpPWpGaD
Apraclonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—POMC—adrenal gland cancer	0.00255	0.00258	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—TSHR—adrenal gland cancer	0.00255	0.00257	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—ZNRF3—adrenal gland cancer	0.00246	0.00249	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—PRKACA—adrenal gland cancer	0.00241	0.00243	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR ligand binding—POMC—adrenal gland cancer	0.00239	0.00242	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—SDHD—adrenal gland cancer	0.00238	0.0024	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—RRM1—adrenal gland cancer	0.00238	0.0024	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—PRKACA—adrenal gland cancer	0.00225	0.00227	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—CDC42—adrenal gland cancer	0.00225	0.00227	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—GNRH1—adrenal gland cancer	0.00223	0.00225	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—MED12—adrenal gland cancer	0.00218	0.0022	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—GNAS—adrenal gland cancer	0.00215	0.00217	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—CDC42—adrenal gland cancer	0.0021	0.00212	CbGpPWpGaD
Apraclonidine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—adrenal gland cancer	0.0021	0.00212	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR ligand binding—POMC—adrenal gland cancer	0.00209	0.00211	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—GNRH1—adrenal gland cancer	0.00208	0.0021	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—CDC42—adrenal gland cancer	0.00204	0.00206	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—SPRY2—adrenal gland cancer	0.00204	0.00206	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—GNAS—adrenal gland cancer	0.00201	0.00203	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—TSHR—adrenal gland cancer	0.00198	0.002	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—PRKACA—adrenal gland cancer	0.00197	0.00199	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—GNAS—adrenal gland cancer	0.00195	0.00197	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR ligand binding—POMC—adrenal gland cancer	0.00194	0.00196	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—CDC42—adrenal gland cancer	0.00191	0.00193	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—SPRY2—adrenal gland cancer	0.0019	0.00192	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MEN1—adrenal gland cancer	0.00187	0.00188	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—TSHR—adrenal gland cancer	0.00185	0.00187	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—CDC42—adrenal gland cancer	0.00184	0.00186	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—PRKACA—adrenal gland cancer	0.00183	0.00185	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—GNAS—adrenal gland cancer	0.00182	0.00184	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—GNRH1—adrenal gland cancer	0.00182	0.00184	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—MED12—adrenal gland cancer	0.00177	0.00179	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—GNAS—adrenal gland cancer	0.00176	0.00177	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MEN1—adrenal gland cancer	0.00174	0.00176	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—CDC42—adrenal gland cancer	0.00171	0.00173	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—GNRH1—adrenal gland cancer	0.00169	0.00171	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—CDC42—adrenal gland cancer	0.00167	0.00169	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—SPRY2—adrenal gland cancer	0.00166	0.00168	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—GNAS—adrenal gland cancer	0.00163	0.00165	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—TSHR—adrenal gland cancer	0.00162	0.00164	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—GNAS—adrenal gland cancer	0.0016	0.00161	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PRKACA—adrenal gland cancer	0.00159	0.00161	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—CDC42—adrenal gland cancer	0.00155	0.00157	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—SPRY2—adrenal gland cancer	0.00154	0.00156	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MEN1—adrenal gland cancer	0.00152	0.00154	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—TSHR—adrenal gland cancer	0.00151	0.00152	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—GNAS—adrenal gland cancer	0.00148	0.0015	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—POMC—adrenal gland cancer	0.00145	0.00146	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PRKACA—adrenal gland cancer	0.00142	0.00144	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MEN1—adrenal gland cancer	0.00142	0.00143	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—POMC—adrenal gland cancer	0.00135	0.00137	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PRKACA—adrenal gland cancer	0.00133	0.00134	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—POMC—adrenal gland cancer	0.00132	0.00133	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PRKACA—adrenal gland cancer	0.00129	0.0013	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—GNAS—adrenal gland cancer	0.00129	0.0013	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—ABCB1—adrenal gland cancer	0.00127	0.00128	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—POMC—adrenal gland cancer	0.00123	0.00124	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CDC42—adrenal gland cancer	0.00121	0.00122	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—POMC—adrenal gland cancer	0.00118	0.00119	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IGF2—adrenal gland cancer	0.00116	0.00118	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PRKACA—adrenal gland cancer	0.00116	0.00117	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—GNAS—adrenal gland cancer	0.00115	0.00117	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CDC42—adrenal gland cancer	0.00113	0.00114	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IGF1R—adrenal gland cancer	0.00113	0.00114	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—POMC—adrenal gland cancer	0.0011	0.00111	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—TP53—adrenal gland cancer	0.00109	0.0011	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IGF2—adrenal gland cancer	0.00109	0.0011	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PRKACA—adrenal gland cancer	0.00108	0.00109	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—GNAS—adrenal gland cancer	0.00108	0.00109	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—POMC—adrenal gland cancer	0.00107	0.00108	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IGF1R—adrenal gland cancer	0.00105	0.00106	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—GNAS—adrenal gland cancer	0.00105	0.00106	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—ABCB1—adrenal gland cancer	0.00103	0.00104	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—TP53—adrenal gland cancer	0.00102	0.00103	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—POMC—adrenal gland cancer	0.000998	0.00101	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CDC42—adrenal gland cancer	0.000986	0.000996	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—TERT—adrenal gland cancer	0.000969	0.000979	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IGF2—adrenal gland cancer	0.000951	0.00096	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—GNAS—adrenal gland cancer	0.000942	0.000952	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IGF1R—adrenal gland cancer	0.000919	0.000928	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CDC42—adrenal gland cancer	0.000916	0.000925	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—TERT—adrenal gland cancer	0.000905	0.000914	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IGF2—adrenal gland cancer	0.000883	0.000892	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—GNAS—adrenal gland cancer	0.000876	0.000884	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—POMC—adrenal gland cancer	0.000868	0.000877	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IGF1R—adrenal gland cancer	0.000854	0.000862	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—BAD—adrenal gland cancer	0.000843	0.000851	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—TP53—adrenal gland cancer	0.000826	0.000834	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—TERT—adrenal gland cancer	0.000791	0.000799	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—BAD—adrenal gland cancer	0.000787	0.000795	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—POMC—adrenal gland cancer	0.000777	0.000785	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—BRAF—adrenal gland cancer	0.000767	0.000775	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—EGFR—adrenal gland cancer	0.000744	0.000751	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—TERT—adrenal gland cancer	0.000735	0.000742	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—POMC—adrenal gland cancer	0.000726	0.000733	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—BRAF—adrenal gland cancer	0.000717	0.000724	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—POMC—adrenal gland cancer	0.000705	0.000712	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—EGFR—adrenal gland cancer	0.000695	0.000702	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PTGS2—adrenal gland cancer	0.000692	0.000699	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—BAD—adrenal gland cancer	0.000688	0.000695	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—BAD—adrenal gland cancer	0.00064	0.000646	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—POMC—adrenal gland cancer	0.000635	0.000641	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—BRAF—adrenal gland cancer	0.000627	0.000633	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—EGFR—adrenal gland cancer	0.000607	0.000613	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—POMC—adrenal gland cancer	0.00059	0.000595	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—BRAF—adrenal gland cancer	0.000582	0.000588	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—EGFR—adrenal gland cancer	0.000564	0.00057	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PTGS2—adrenal gland cancer	0.000562	0.000568	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CTNNB1—adrenal gland cancer	0.000555	0.00056	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CTNNB1—adrenal gland cancer	0.000518	0.000523	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CTNNB1—adrenal gland cancer	0.000453	0.000457	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—EGFR—adrenal gland cancer	0.000439	0.000444	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CTNNB1—adrenal gland cancer	0.000421	0.000425	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—EGFR—adrenal gland cancer	0.00041	0.000414	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—TP53—adrenal gland cancer	0.000369	0.000373	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—EGFR—adrenal gland cancer	0.000359	0.000362	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—TP53—adrenal gland cancer	0.000345	0.000348	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—EGFR—adrenal gland cancer	0.000333	0.000337	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—TP53—adrenal gland cancer	0.000301	0.000304	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—TP53—adrenal gland cancer	0.00028	0.000283	CbGpPWpGaD
